Congratulations to Miller Lab member Kathleen Schoch on her publication!
Dr. Kathleen Schoch is a postdoctoral research assistant in the Miller Lab who focuses on dementias characterized by the pathological accumulation of the protein “tau”. She published a paper in Neuron that examined the potential of a unique tau-lowering therapeutic strategy to treat Alzheimer’s disease, and another of Dr. Schoch’s papers was recently accepted for publication in Neuron as well. This new publication highlights the clinical strides that antisense oligonucleotides (ASOs) have made toward treating neurodegenerative diseases, including ALS and Alzheimer’s disease.
“We’re enthusiastic about the progress ASOs have made and how they continue to develop,” Dr. Schoch states. “Notably, the ASO Spinraza (nusinersen) recently achieved FDA approval for the treatment of the devastating childhood disease, spinal muscular atrophy. Successes like these help to motivate my own research toward developing a treatment for tau-related dementias.”